Synthetic Biologics Inc (SYN) Downgraded to “Sell” at BidaskClub
Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.
SYN has been the subject of a number of other research reports. Zacks Investment Research cut Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine upgraded Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.92.
Synthetic Biologics (NYSEMKT:SYN) opened at $0.79 on Friday. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.60.
Synthetic Biologics (NYSEMKT:SYN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.10).
COPYRIGHT VIOLATION WARNING: “Synthetic Biologics Inc (SYN) Downgraded to “Sell” at BidaskClub” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/synthetic-biologics-inc-syn-downgraded-to-sell-at-bidaskclub/1677479.html.
A number of institutional investors have recently bought and sold shares of SYN. Goldman Sachs Group Inc. increased its position in Synthetic Biologics by 8,102.7% during the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after acquiring an additional 1,115,343 shares during the last quarter. LMR Partners LLP purchased a new stake in Synthetic Biologics during the second quarter valued at $194,000. Susquehanna International Group LLP grew its holdings in Synthetic Biologics by 76.4% during the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after purchasing an additional 82,030 shares during the period. Creative Planning grew its holdings in Synthetic Biologics by 65.4% during the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after purchasing an additional 70,000 shares during the period. Finally, UBS Group AG grew its holdings in Synthetic Biologics by 10.3% during the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after purchasing an additional 20,038 shares during the period.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.